Document Detail

Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting.
MedLine Citation:
PMID:  20562445     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Bilirubin, an effective antioxidant, shows a large variation in levels between individuals and has been positively associated with reduced cardiovascular disease risk. A major reason for the variability is a common promoter polymorphism, UGT1A1*28, which reduces the transcription of the enzyme that conjugates bilirubin, UDP-glucuronosyltransferase 1A1. The aim of the study was to evaluate a possible protective effect of plasma bilirubin and the UGT1A1*28 polymorphism against myocardial infarction in a prospective case-referent setting.
METHODS AND RESULTS: Subjects (n=618) with a first-ever myocardial infarction (median event age, 60.5 years; median lag time, 3.5 years) and 1184 matched referents were studied. Plasma bilirubin was lower in cases versus referents. Despite a strong gene-dosage effect on bilirubin levels in both cases and referents, the UGT1A1*28 polymorphism did not influence the risk of myocardial infarction. Among multiple other variables, serum iron showed one of the strongest associations with bilirubin levels.
CONCLUSIONS: We found no evidence for a protective effect of the UGT1A1*28 polymorphism against myocardial infarction and consequently neither for bilirubin. The lower bilirubin levels in cases might be caused by decreased production, increased degradation, or increased elimination.
Kim Ekblom; Stefan L Marklund; Jan-Håkan Jansson; Pia Osterman; Göran Hallmans; Lars Weinehall; Johan Hultdin
Related Documents :
20304615 - -94 ins/del attg nfkb1 gene variant is associated with lower susceptibility to myocardi...
15380495 - Macrophage migration inhibitory factor and the risk of myocardial infarction or death d...
3321985 - Atherosclerosis and its evolution in childhood.
3493315 - Augmented hageman factor and prolactin titers, enhanced cold activation of factor vii, ...
23581555 - Effect of pimobendan in addition to standard therapy for heart failure on prevention of...
10653675 - Optimizing the initial 12-lead electrocardiographic diagnosis of acute myocardial infar...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-19
Journal Detail:
Title:  Circulation. Cardiovascular genetics     Volume:  3     ISSN:  1942-3268     ISO Abbreviation:  Circ Cardiovasc Genet     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-18     Completed Date:  2010-12-02     Revised Date:  2014-03-28    
Medline Journal Info:
Nlm Unique ID:  101489144     Medline TA:  Circ Cardiovasc Genet     Country:  United States    
Other Details:
Languages:  eng     Pagination:  340-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age of Onset
Bilirubin / blood*
Case-Control Studies
Cohort Studies
Cytoprotection / genetics
Gene Dosage / physiology
Glucuronosyltransferase / genetics*
Middle Aged
Myocardial Infarction / blood*,  epidemiology,  genetics*
Polymorphism, Genetic* / physiology
Prospective Studies
Reg. No./Substance:
EC 2.4.1.-/UGT1A1 enzyme; EC; RFM9X3LJ49/Bilirubin
Comment In:
Circ Cardiovasc Genet. 2011 Feb;4(1):e1; author reply e2   [PMID:  21325152 ]
Circ Cardiovasc Genet. 2010 Aug;3(4):308-10   [PMID:  20716749 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association of genetic risk variants with expression of proximal genes identifies novel susceptibili...
Next Document:  A comprehensive genetic study on left atrium size in Caribbean Hispanics identifies potential candid...